Induction Healthcare Group PLC
("Induction", the "Company", or the "Group")
Block Listing Six Monthly Return
Induction Healthcare (AIM: INHC), a leading digital health platform driving transformation of healthcare systems worldwide, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:
| Name of applicant: | Induction Healthcare Group PLC
LEI: 213800RY96GCZQW5TP19
| ||||
| Name of scheme: | The Induction Healthcare NTA Share Option Plan
| ||||
| Period of return:
| From: | 26/01/2022 | To: | 26/07/2022
| |
| Number and class of securities originally admitted and the date of admission
| 3,500,000 ordinary shares on 26 July 2021 | ||||
| Balance of unallotted securities under scheme(s) from initial application:
| 3,500,000 | ||||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
| nil | ||||
| Less: Number of securities issued/allotted under scheme(s) during the period:
| 396,567 | ||||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period:
| 3,103,433 | ||||
| Contact: | Alison Talbot, Company Secretary +44 (0) 3339 398 091 | ||||
| | | | | | |
ENQUIRIES
| Induction James Balmain, Chief Executive Officer Guy Mitchell, Chief Financial Officer | Via Walbrook PR Ltd: induction@walbrookpr.com |
| |
|
| Singer Capital Markets (Nominated Adviser and Broker) | +44 (0) 20 7496 3000 |
| Philip Davies / Kailey Aliyar |
|
| |
|
| Walbrook PR Ltd | induction@walbrookpr.com |
| Paul McManus / Alice Woodings | Mob: +44(0)7980 541 893 / +44 (0)7407 804 654 |
About Induction - www.inductionhealthcare.com
Induction (AIM: INHC) Induction delivers a suite of software solutions through a single integrated platform that transforms care delivery. Our system-wide applications help healthcare providers and administrators to deliver care at any stage remotely as well as face-to-face - giving the communities they serve greater flexibility, control and ease of access. Purpose-built for integration with leading Electronic Medical Record (EMR) platforms, our products offer immediate stand-alone value that becomes even greater when integrated with pre-existing systems.
Used at scale by national and regional healthcare systems, as well non-health government services, our applications are relied upon by hundreds of thousands of clinicians and millions of patients across almost every hospital in the British Isles.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
